What is ARIA CV?
ARIA CV is a pioneering medical technology firm dedicated to the development of a novel, implantable device designed to treat pulmonary hypertension. Unlike traditional interventions that rely on batteries, pumps, or complex electronics, the ARIA CV solution utilizes a sophisticated reservoir and balloon system connected by a conduit. This mechanical design operates in harmony with the natural rhythm of the heart, offering a passive, highly durable alternative for patients suffering from this debilitating condition. By focusing on physiological integration rather than external power sources, the company is carving out a unique niche in the cardiovascular device market, appealing to healthcare providers and clinical researchers who prioritize long-term patient outcomes and reduced maintenance requirements.
How much funding has ARIA CV raised?
ARIA CV has raised a total of $40.2M across 3 funding rounds:
Series A
$7.8M
Series B
$31M
Stock/Share Issuance
$1.4M
Series A (2015): $7.8M with participation from Broadview Ventures, Catalyst Health Ventures, Cedar Point Capital, and BioStar Capital
Series B (2020): $31M, investors not publicly disclosed
Stock/Share Issuance (2025): $1.4M, investors not publicly disclosed
Key Investors in ARIA CV
Broadview Ventures
Broadview Ventures is a specialized impact investor focused on cardiovascular disease and stroke, dedicated to accelerating the development of innovative medical technologies.
BioStar Capital
BioStar Capital is a healthcare-focused investment firm that integrates clinical expertise with financial acumen to support transformative medical device innovations.
Catalyst Health Ventures
Catalyst Health Ventures leverages a global network to foster health innovation, facilitating strategic partnerships and market access for emerging medical technology companies.
What's next for ARIA CV?
With the recent influx of capital, ARIA CV is well-positioned to accelerate its clinical investigation programs and refine its manufacturing processes. The strategic focus will likely shift toward scaling production capabilities and gathering the longitudinal data necessary for regulatory approval. As the company transitions into this more mature lifecycle stage, the emphasis will remain on demonstrating the efficacy and safety of its heart-driven technology in broader patient populations. Investors and industry stakeholders will be closely monitoring the firm's progress as it moves closer to commercialization, potentially disrupting the current standard of care for pulmonary hypertension patients globally.
See full ARIA CV company page
